Lim, Bora
Murthy, Rashmi K.
Lee, Jangsoon
Jackson, Summer A.
Iwase, Toshiaki
Davis, Darren W.
Willey, Jie S.
Wu, Jimin
Shen, Yu
Tripathy, Debu
Alvarez, Ricardo
Ibrahim, Nuhad K.
Brewster, Abenaa M.
Barcenas, Carlos H.
Brown, Powel H.
Giordano, Sharon H.
Moulder, Stacy L.
Booser, Daniel J.
Moscow, Jeffrey A.
Piekarz, Richard
Valero, Vicente
Ueno, Naoto T.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI #8871)
Article History
Received: 22 May 2018
Revised: 8 April 2019
Accepted: 25 April 2019
First Online: 17 May 2019
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki and was approved by institutional review boards at The University of Texas MD Anderson Cancer Center. All enroled patients provided written informed consent.
: All authors consent the material to publish.
: The authors declare no competing interests.
: All data generated or analysed during this study are included in this published article [and its InternalRef removed].
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
: This study was supported by the National Cancer Institute at the National Institutes of Health through a Cancer Therapy Evaluation Program UM1 grant [NCI #8871] and MD Anderson’s Cancer Center Support Grant [P30CA016672; used the Clinical Trials Support Resource and Biostatistics Resource Group]; MD Anderson’s Center for Genetics and Genomics (used the Molecular Cytogenetics Facility); and the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic.